Figure 6: Cell model of synthetic viability between BRCA2 and PARP1 deficiency.
From: Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
Model to explain the difference between synthetic viability and synthetic lethality associated with BRCA2 and PARP1 loss. The outcome is dependent on the order of events. When BRCA2 loss is followed by PARP inhibition or PARP1 deficiency, it results in synthetic lethality (right). In contrast, when PARP inhibition or PARP1 deficiency is followed by BRCA2 loss, it results in synthetic viability (middle).
